


PHARMACEUTICAL 2022

Nuvalent Inc. Rank 25 of 466







PHARMACEUTICAL 2022



Nuvalent Inc. Rank 25 of 466

The relative strengths and weaknesses of Nuvalent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nuvalent Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Nuvalent Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 293%, being 215% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	290,628
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,787
Liabilities, Non-Current	0
Other Assets	3,196
Other Compr. Net Income	-228
Other Expenses	0
Other Liabilities	0
Other Net Income	-521
Other Revenues	0
Property and Equipment	0
Research and Development	35,559
Selling, General and Administrative Expense	10,258

Output Variable	Value in 1000 USD
Assets	293,824
Liabilities	8,787
Expenses	45,817
Revenues	0
Stockholders Equity	285,037
Net Income	-46,338
Comprehensive Net Income	-46,452
Economic Capital Ratio	293%

